Literature DB >> 12537937

Cytoreductive nephrectomy in metastatic renal cancer.

Robert C Flanigan1.   

Abstract

Recent randomized prospective trials have suggested that cytoreductive nephrectomy confers a survival advantage in patients with metastatic renal cancer who receive immunotherapy with interferon-alfa-2b. It appears that the patients most benefiting from this approach are those with good performance status, lung-only metastases, and adequate cardiac and pulmonary reserve. Nonrandomized trials have further suggested that this survival advantage may be extended in patients who receive more aggressive interleukin-2-based immunotherapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12537937     DOI： 10.1007/s11934-003-0055-6

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


  23 in total

1.  Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study.

Authors:  W F Spencer; W M Linehan; M M Walther; G P Haas; M T Lotze; S L Topalian; J C Yang; M J Merino; J R Lange; B A Pockaj
Journal:  J Urol       Date:  1992-01       Impact factor: 7.450

2.  Cancer statistics, 2000.

Authors:  R T Greenlee; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  2000 Jan-Feb       Impact factor: 508.702

3.  Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.

Authors:  C N Robertson; W M Linehan; H I Pass; L G Gomella; G P Haas; A Berman; M Merino; S A Rosenberg
Journal:  J Urol       Date:  1990-09       Impact factor: 7.450

4.  Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma.

Authors:  M M Walther; J C Yang; H I Pass; W M Linehan; S A Rosenberg
Journal:  J Urol       Date:  1997-11       Impact factor: 7.450

5.  Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.

Authors:  M L Fallick; D F McDermott; D LaRock; J P Long; M B Atkins
Journal:  J Urol       Date:  1997-11       Impact factor: 7.450

6.  Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials.

Authors:  T Umeda; T Niijima
Journal:  Cancer       Date:  1986-09-15       Impact factor: 6.860

7.  The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma.

Authors:  R Rackley; A Novick; E Klein; R Bukowski; D McLain; D Goldfarb
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

8.  Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens.

Authors:  J S Wolf; F R Aronson; E J Small; P R Carroll
Journal:  J Surg Oncol       Date:  1994-01       Impact factor: 3.454

9.  Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.

Authors:  S Mani; M B Todd; K Katz; W J Poo
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

Review 10.  Renal cell carcinoma: management of advanced disease.

Authors:  R A Figlin
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450
View more
  2 in total

1.  Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy.

Authors:  Arun Z Thomas; Mehrad Adibi; Leonardo D Borregales; Ly N Hoang; Pheroze Tamboli; Eric Jonasch; Nizar M Tannir; Surena F Matin; Christopher G Wood; Jose A Karam
Journal:  J Urol       Date:  2015-03-07       Impact factor: 7.450

2.  The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis.

Authors:  Arun Z Thomas; Mehrad Adibi; Rebecca S Slack; Leonardo D Borregales; Megan M Merrill; Pheroze Tamboli; Kanishka Sircar; Eric Jonasch; Nizar M Tannir; Surena F Matin; Christopher G Wood; Jose A Karam
Journal:  J Urol       Date:  2016-03-29       Impact factor: 7.450
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.